SCHEMBL267474

SCHEMBL267474

Cc1ccc(C=NNC(=O)c2c(NC(=O)c3cccc(CN(CC(C)O)CC(C)O)c3)sc(C)c2C)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 7/20 0.41
ALDH1A1 P00352 6/20 0.40
HPGD P15428 6/20 0.40
MAPT P10636 5/20 0.40
LMNA P02545 3/20 0.40
PLA2G1B P04054 1/20 0.40
MAPK1 P28482 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
TSHR P16473 1/20 0.39
RECQL P46063 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
POLB P06746 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267473 1.00 SLC34A2 (0.41) SLC34A2ALDH1A1HPGDMAPTLMNA
SCHEMBL266005 0.92 NPC1 (0.44) SLC34A2ALDH1A1HPGDMAPTLMNA
SCHEMBL266006 0.92 NPC1 (0.44) SLC34A2ALDH1A1HPGDMAPTLMNA
SCHEMBL268027 0.91 RAB9A (0.47) SLC34A2ALDH1A1HPGDMAPTLMNA
SCHEMBL268028 0.91 RAB9A (0.47) SLC34A2ALDH1A1HPGDMAPTLMNA
SCHEMBL267806 0.89 MAPT (0.44) ALDH1A1HPGDMAPTLMNAMAPK1
SCHEMBL267805 0.89 MAPT (0.44) ALDH1A1HPGDMAPTLMNAMAPK1
SCHEMBL265236 0.88 SLC34A2 (0.39) SLC34A2ALDH1A1HPGDMAPTLMNA
SCHEMBL265237 0.88 SLC34A2 (0.39) SLC34A2ALDH1A1HPGDMAPTLMNA
SCHEMBL268523 0.88 SLC34A2 (0.38) SLC34A2ALDH1A1HPGDMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885ALDH1A1 3022/4885HPGD 2509/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885ALDH1A1 2872/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.